The Cambridge, Mass.-based company’s neuro-spinal scaffold is a novel, biodegradable device designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting.
Results from the trial were presented at the 2019 AANS Meeting in San Diego, InVivo Therapeutics said.
Of the 16 patients in the trial, 44%, or 7, showed an ASIA Impairment Scale (AIS) conversion at six months, which served as the trial’s primary endpoint, passing the objective performance criterion of the study which was defined at a 25% AIS conversion rate.
Of those patients, six were later evaluated at the 12-month exam as a single patient was lost prior to the follow-up exam, InVivo said. Two of the six remaining patients were assessed to have an AIS B spinal cord injury at six months taht improved to an AIS C SCI at 12 months.
“In addition to focusing on enrollment in the INSPIRE 2.0 Study, we look forward to continuing to follow this cohort of INSPIRE patients through their 24-month follow up visit, and we remain encouraged by the continued stability of the AIS conversion rates,” prez & CEO Dr. Richard Toselli said in a press release.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.